You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Litigation Details for Reckitt Benckiser LLC v. Aurobindo Pharma Limited (D. Del. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Reckitt Benckiser LLC v. Aurobindo Pharma Limited
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .

Details for Reckitt Benckiser LLC v. Aurobindo Pharma Limited (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2016-08-12 100 Stark from Pilar G. Kraman regarding U.S. Patent No. 6,372,252. (Kraman, Pilar) (Entered: 08/12/2016) …2014 13 March 2017 1:14-cv-01203 830 Patent None District Court, D. Delaware External link to document
2016-09-01 116 infringement of U.S Patent Nos. 6,372,252 (the “’252 Patent”), 6,955,821 (the “’821 Patent”) and 7,838,0327,838,032 (the “’032 Patent”) (the “Patents-in-Suit”) on or about September 17, 2014.2 During fact discovery…only characterizes the patents in general.3 In fact, each of the asserted patent claims requires certain… administration. See, e.g., ’821 patent claims 1 and 29, ‘032 patent claim 1. Aurobindo’s ANDA product…Hearing, unlike the ’252 patent at issue in Watson, the ’821 and ’032 patents at issue here have no separate External link to document
2016-09-15 125 Robert S. Langer Regarding Validity of U.S. Patents Nos. 6,955,821 and 7,838,032 filed by Reckitt Benckiser…2014 13 March 2017 1:14-cv-01203 830 Patent None District Court, D. Delaware External link to document
2016-11-03 134 alleging infringement of U.S. Patent Nos. 6,372,252 (the "'252 patent"), 6,955,821 (the …;'821 patent"), and 7;838,032 (the· "'032 patent"). 1 The patents are directed…;It is a bedrock principle of patent law that the claims ofa patent define the invention to which…reading the entire patent." Id. at 13 21 (internal quotation marks omitted). The patent specification…the context of the '032 patent-in-suit, because the '032 patent issued from an application that External link to document
2017-03-05 174 29, 30, 41, and 42 of U.S. Patent No. 6,955,821 and claim 1 of U.S. Patent No. 7,838,032. (See D.I. 148…the '032 patent includes a limitation comparable to that found in the '821 patent. Specifically… contradicted by the patents in suit. Both the '821 and '032 patents describe single-formulation… products. See '821 patent col. 61. 64 ·-col. 111. 55; '032 patent col. 11 1. 9 - col. 161. … Table 2. The '032 patent presents the same data. See '032 patent col. 26 l 33 ·.. col. 291 External link to document
2017-10-16 222 . i 1 6,955,821 and 7,838,032, which claim controlled-release … exceptionality. In particular, one patent (the '252 patent) initially asserted in this case - but…Benckiser sued Auropindo for infringement of U.S. Patent Nos. … 1 . Reckitt initially asserted U.S. Patent No. 6,3172,252 as well. (See D.I. 1) …11) 2. In "exceptional" patent cases, a Col may award "reasonable attorney External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.